Chemotherapy for Mesothelioma: Types, Effectiveness, Combinations & Side Effects

Overview of Chemotherapy in Mesothelioma Treatment

Chemotherapy is a cornerstone of systemic therapy for malignant mesothelioma, an aggressive cancer linked to asbestos exposure. While not curative in most advanced cases, it can shrink tumors, prolong survival, and improve quality of life. Treatment is highly individualized based on mesothelioma type (pleural, peritoneal, etc.), stage, patient health, and biomarker status.

First-Line Chemotherapy Regimens

Pemetrexed (Alimta) + Platinum Agent (Cisplatin or Carboplatin): The standard first-line combination for unresectable pleural mesothelioma, based on a landmark phase III trial showing superior survival over cisplatin alone. Carboplatin is often substituted for cisplatin to reduce toxicity (neuropathy, nephrotoxicity, ototoxicity).
Gemcitabine + Platinum: An alternative, particularly if pemetrexed is contraindicated or unavailable.
Vinorelbine + Platinum: Another option with activity in mesothelioma.

For peritoneal mesothelioma, systemic chemotherapy is less effective than cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), but may be used neoadjuvantly or for unresectable disease.

Second-Line & Subsequent Therapies

No universally accepted standard exists after first-line progression. Options include:

Single-agent pemetrexed (if not used first-line or long treatment-free interval)
Vinorelbine (Navelbine)
Gemcitabine (Gemzar)
Docetaxel (Taxotere)
Immune checkpoint inhibitors (ICIs): Nivolumab ± ipilimumab, pembrolizumab—show activity in some trials, especially in PD-L1+ or high tumor mutational burden tumors. FDA-approved nivolumab + ipilimumab as first-line for unresectable pleural mesothelioma (CheckMate 743).
Targeted therapies: Clinical trials exploring anti-angiogenics (bevacizumab), mesothelin-targeted agents, ADCs, etc.

Effectiveness & Response Factors

Response rates: ~30–40% partial response with pemetrexed/platinum; disease control rate (stable disease + response) ~80%.
Median overall survival: ~12–18 months with first-line chemo; ~18+ months with nivolumab/ipilimumab in CheckMate 743.
Predictive factors: Good performance status (ECOG 0–1), epithelioid histology, normal LDH, no chest pain, female sex, younger age correlate with better outcomes.
Biomarkers: BAP1 loss, PD-L1 expression, tumor mutational burden under investigation for ICI selection.

Combination & Multimodal Approaches

Surgery + Chemo: Neoadjuvant or adjuvant chemo around extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D) for select early-stage patients.
Radiation + Chemo: Hemithoracic radiation post-EPP or palliative RT for symptom control.
Immunotherapy + Chemo: Trials combining ICIs with pemetrexed/platinum (e.g., DREAM, KEYNOTE-483).
Bevacizumab + Chemo: MAPS trial showed survival benefit adding bevacizumab to pemetrexed/cisplatin.

Key Side Effects & Management

Side Effect	Incidence	Management
Fatigue	Very common	Activity pacing, treat anemia, rule out hypothyroidism
Nausea/Vomiting	Common (esp. cisplatin)	5-HT3 antagonists (ondansetron), NK1 antagonists (aprepitant), dexamethasone
Myelosuppression (neutropenia, anemia, thrombocytopenia)	Common	Growth factors (G-CSF), transfusions, dose delays/reductions
Neuropathy	Cisplatin-specific	Dose reduction, switch to carboplatin, duloxetine for symptomatic relief
Nephrotoxicity	Cisplatin-specific	Aggressive hydration, magnesium/potassium replacement, avoid nephrotoxins
Ototoxicity	Cisplatin-specific	Baseline & serial audiograms, dose modification
Mucositis, diarrhea, rash	Pemetrexed-related	Folic acid & vitamin B12 supplementation (mandatory), loperamide, topical steroids

Special Considerations

Folic acid (350–1000 mcg daily) and vitamin B12 (1000 mcg IM every 9 weeks) are mandatory with pemetrexed to reduce hematologic and GI toxicity.
Renal function: Cisplatin requires CrCl ≥60 mL/min; carboplatin preferred if impaired.
Geriatric assessment: Frailty, comorbidities, and polypharmacy guide regimen choice and supportive care intensity.
Clinical trials: Strongly encouraged at all stages; many novel agents (ADCs, CAR-T, targeted therapies) are in development.

Conclusion

Chemotherapy remains a vital tool in mesothelioma management. The pemetrexed/platinum backbone, now complemented by immunotherapy combinations, offers meaningful survival benefit for many. Ongoing research aims to refine patient selection, overcome resistance, and integrate novel agents into curative-intent multimodal strategies. Decisions should be made in consultation with a multidisciplinary mesothelioma team.